Clinical Trial Detail

NCT ID NCT02278120
Title Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

Her2-receptor negative breast cancer

Therapies

Tamoxifen

Letrozole

Ribociclib

Goserelin

Anastrozole

Age Groups: adult

Additional content available in CKB BOOST